Multiple Myeloma

GEM-POMCIDEX Study: Treatment of Patients with RRMM Using Pomalidomide, Cyclophosphamide, and Dexamethasone (POMCIDEX)

Comparing consolidation treatment with bortezomib + lenalidomide + dexamethasone (VRD) followed by lenalidomide maintenance with lenalidomide maintenance alone, the former approach was superior regarding progression-free survival (PFS) and myeloma response in patients with newly diagnosed multiple myeloma (MM) with an acceptable toxicity profile. Read More ›

Assessment of Options for Patients with RRMM with Triple-Class Exposure: Literature Review Indicates Urgent Need for New Treatments

This multicenter, retrospective, real-world study (GEM-POMCIDEX) was initiated to evaluate the effectiveness of the guidelines established by the Spanish Myeloma Group (PETHEMA) to treat appropriate patients with relapsed/refractory multiple myeloma (RRMM) with pomalidomide, cyclophosphamide, and dexamethasone (POMCIDEX). Read More ›

Definition and Prediction of Unsustained Complete Remission in Patients with Transplant-Eligible MM

Poor response on subsequent therapies is typically seen in patients with relapsed/refractory multiple myeloma (RRMM) who have had 3 prior lines of therapy with immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies. In addition, challenges for future treatment options are presented. Read More ›

MRD Status Comparison by 3 Techniques in Patients with Newly Diagnosed Transplant-Eligible MM

Recent studies have illustrated complete response (CR) rates >50% for transplant-eligible patients with multiple myeloma (MM) treated with optimized induction followed by high-dose therapy (HDT) and autologous stem-cell transplantation (ASCT). However, many patients relapse early. Patients who relapse are generally thought to have very low survival rates. Read More ›

What is Minimal Residual Disease (MRD) Negativity?

According to data from the phase 2 FORTE trial, 3 different techniques were analyzed and compared to characterize minimal residual disease (MRD), including positron emission tomography/computed tomography (PET/CT), multiparameter flow cytometry (MFC), and next-generation sequencing (NGS). Read More ›

Multiple Myeloma as a Chronic Disease

Leslie Lauersdorf breaks down what it means to be MRD negative and how she explains MRD negativity to her patients. Read More ›

As multiple myeloma moves toward being considered a chronic disease, nurses and navigators have new considerations to keep in mind when treating their patients. Read More ›

Triplets versus Quads

CAR T-Cell Data in Multiple Myeloma

Leslie Lauersdorf explains triplet versus quad regimens in relation to multiple myeloma. Read More ›

Latest Developments in Multiple Myeloma

Leslie Lauersdorf discusses key considerations for nurses and navigators surrounding the use of CAR T-cell therapy in multiple myeloma. Read More ›